An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities, Am J Obstet Gynecol. 1 avr, vol.148, issue.7, pp.886-94, 1984. ,
Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities, vol.7, pp.623-653, 1987. ,
,
, First-trimester free beta (hCG) screening for Down syndrome, Prenat Diagn. juill, vol.13, issue.7, pp.557-62, 1993.
,
, Low second trimester maternal serum unconjugated oestriol in pregnancies with Down's syndrome, Br J Obstet Gynaecol. avr, vol.95, issue.4, pp.330-333, 1988.
Free beta human choriogonadotropin in Down's syndrome screening: a multicentre study of its role compared with other biochemical markers, Ann Clin Biochem. sept, vol.29, pp.506-524, 1992. ,
,
, Maternal serum free beta hCG screening: results of studies including 480 cases of Down syndrome, Prenat Diagn. févr, vol.14, issue.2, pp.97-103, 1994.
Integrating antenatal Down's syndrome screening, Curr Opin Obstet Gynecol. avr, vol.13, issue.2, pp.175-81, 2001. ,
Fetal nuchal translucency: ultrasound screening for fetal trisomy in the first trimester of pregnancy, Br J Obstet Gynaecol. sept, vol.101, issue.9, pp.782-788, 1994. ,
,
Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10 to 14 weeks of gestation, Br J Obstet Gynaecol. déc, vol.102, issue.12, pp.957-62, 1995. ,
UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchaltranslucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group, Lancet Lond Engl. 1 août, vol.352, issue.9125, pp.343-349, 1998. ,
The effect of nuchal translucency measurement on second-trimester biochemical screening for Down's syndrome ,
, Ultrasound Obstet Gynecol Off J Int Soc Ultrasound Obstet Gynecol. avr, vol.9, issue.4, pp.244-251, 1997.
Effect of first-trimester nuchal translucency on second-trimester maternal serum biochemical screening for Down's syndrome, Ultrasound Obstet Gynecol Off J Int Soc Ultrasound Obstet Gynecol. oct, vol.10, issue.4, pp.261-265, 1997. ,
,
Screening for Down syndrome using first-trimester ultrasound and secondtrimester maternal serum markers in a low-risk population: a prospective longitudinal study, Ultrasound Obstet Gynecol Off J Int Soc Ultrasound Obstet Gynecol. juill, vol.18, issue.1, pp.26-31, 2001. ,
,
Down's syndrome screening with nuchal translucency at 12(+0)-14(+0) weeks and maternal serum markers at 14(+1)-17(+0) weeks: a prospective study, Hum Reprod Oxf Engl. avr, vol.17, issue.4, pp.1093-1101, 2002. ,
Free beta-hCG as firsttrimester marker for fetal trisomy, Lancet Lond Engl. 13 juin, vol.339, issue.8807, p.1480, 1992. ,
First trimester serum screening for Down's syndrome, Prenat Diagn. déc, vol.15, issue.13, pp.1227-1267, 1995. ,
Serum PAPP-A measurements in first-trimester screening for Down syndrome, Prenat Diagn, vol.13, issue.10, pp.903-911, 1993. ,
,
Low maternal serum levels of pregnancy associated plasma protein A (PAPP-A) in the first trimester in association with abnormal fetal karyotype, Br J Obstet Gynaecol. avr, vol.100, issue.4, pp.324-330, 1993. ,
,
, Presence of fetal DNA in maternal plasma and serum, Lancet Lond Engl. 16 août, vol.350, issue.9076, pp.485-492, 1997.
,
, Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis, Am J Hum Genet. avr, vol.62, issue.4, pp.768-75, 1998.
Correlation of fetal DNA and human chorionic gonadotropin concentrations in second-trimester maternal serum, Clin Chem. févr, vol.48, issue.2, pp.386-394, 2002. ,
Rapid clearance of fetal DNA from maternal plasma, Am J Hum Genet. janv, vol.64, issue.1, pp.218-242, 1999. ,
New strategy for prenatal diagnosis of X-linked disorders, N Engl J Med. 9 mai, vol.346, issue.19, p.1502, 2002. ,
Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma, N Engl J Med. 10 déc, vol.339, issue.24, pp.1734-1742, 1998. ,
Analysis of cellfree DNA in maternal blood in screening for aneuploidies: updated meta-analysis ,
, Ultrasound Obstet Gynecol Off J Int Soc Ultrasound Obstet Gynecol. sept, vol.50, issue.3, pp.302-316, 2017.
,
Accuracy of non-invasive prenatal testing using cell-free DNA for detection of Down, Edwards and Patau syndromes: a systematic review and meta-analysis, BMJ Open. 18 janv, vol.6, issue.1, p.10002, 2016. ,
,
Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women, Cochrane Database Syst Rev, vol.10, p.11767, 2017. ,
Cell-free DNA analysis in maternal plasma in cases of fetal abnormalities detected on ultrasound examination, Obstet Gynecol. juin, vol.125, issue.6, pp.1330-1337, 2015. ,
,
, Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma, Proc Natl Acad Sci U S A. 23 déc, vol.105, issue.51, pp.20458-63, 2008.
Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing, Obstet Gynecol. mai, vol.119, issue.5, pp.890-901, 2012. ,
Clinical application of massively parallel sequencing-based prenatal noninvasive fetal trisomy test for trisomies 21 and 18 in 11,105 pregnancies with mixed risk factors, Prenat Diagn. déc, vol.32, issue.13, pp.1225-1257, 2012. ,
,
, Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting, Am J Obstet Gynecol. mars, vol.204, issue.3, pp.205-206, 2011.
Noninvasive prenatal screening for fetal trisomies 21, 18, 13 and the common sex chromosome aneuploidies from maternal blood using massively parallel genomic sequencing of DNA, Am J Obstet Gynecol, vol.211, issue.4, pp.365-366, 2014. ,
,
DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study, Genet Med Off J Am Coll Med Genet, vol.13, issue.11, pp.913-933, 2011. ,
Maternal plasma cell-free fetal and maternal DNA at 11-13 weeks' gestation: relation to fetal and maternal characteristics and pregnancy outcomes, Fetal Diagn Ther, vol.33, issue.4, pp.215-238, 2013. ,
Clinical experience of noninvasive prenatal testing with cell-free DNA for fetal trisomies 21, 18, and 13, in a general screening population, N Engl J Med. 7 août, vol.371, issue.6, pp.580-583, 2013. ,
,
, Implementation of maternal blood cell-free DNA testing in early screening for aneuploidies, Ultrasound Obstet Gynecol Off J Int Soc Ultrasound Obstet Gynecol. juill, vol.42, issue.1, pp.34-40, 2013.
,
Cell-free fetal DNA versus maternal serum screening for trisomy 21 in pregnant women with and without assisted reproduction technology: a prospective interventional study, Genet Med Off J Am Coll Med Genet. 1 mars, 2018. ,
Prise en charge et santé périnatale en cas de grossesse gémellaire : situation en 2010 et évolution récente en France, J Gynécologie Obstétrique Biol Reprod. févr, vol.44, issue.2, pp.184-93, 2015. ,
Les naissances et les établissements, situation et évolution depuis 2010 -Ministère des Solidarités et de la Santé, 2016. ,
Systematic review of screening for trisomy 21 in twin pregnancies in first trimester combining nuchal translucency and biochemical markers: a meta-analysis, Prenat Diagn, vol.34, issue.11, pp.1077-83, 2014. ,
Second-trimester Down syndrome maternal serum marker screening: a prospective study of 11 040 twin pregnancies, Prenat Diagn. déc, vol.28, issue.12, pp.1105-1114, 2008. ,
A reassessment of biochemical marker distributions in trisomy 21-affected and unaffected twin pregnancies in the first trimester, Ultrasound Obstet Gynecol Off J Int Soc Ultrasound Obstet Gynecol. janv, vol.37, issue.1, pp.38-47, 2011. ,
,
Multivariate analysis identifies the estradiol level at ovulation triggering as an independent predictor of the first trimester pregnancy-associated plasma protein-A level in IVF/ICSI pregnancies, Hum Reprod Oxf Engl, vol.28, issue.10, pp.2636-2678, 2013. ,
,
, Additive effect of factors related to assisted conception on the reduction of maternal serum pregnancy-associated plasma protein A concentrations and the increased false-positive rates in first-trimester Down syndrome screening, Fertil Steril, vol.100, issue.5, pp.1314-1334, 2013.
Amniocentesis in twin pregnancies: a systematic review of the literature, Prenat Diagn. mai, vol.32, issue.5, pp.409-425, 2012. ,
Pregnancy loss after chorionic villus sampling and genetic amniocentesis in twin pregnancies: a systematic review, Ultrasound Obstet Gynecol Off J Int Soc Ultrasound Obstet Gynecol. août, vol.40, issue.2, pp.128-162, 2012. ,
, Society for Maternal-Fetal Medicine (SMFM) Publications Committee. Electronic address: esteele@smfm.org. SMFM Statement: clarification of recommendations regarding cell-free DNA aneuploidy screening, Committee Opinion Summary No, vol.640, issue.3, pp.753-757, 2015.
Clinical implementation of routine screening for fetal trisomies in the UK NHS: cell-free DNA test contingent on results from first-trimester combined test, Ultrasound Obstet Gynecol Off J Int Soc Ultrasound Obstet Gynecol. janv, vol.47, issue.1, pp.45-52, 2016. ,
,
Trial by Dutch laboratories for evaluation of non-invasive prenatal testing. Part I-clinical impact, Prenat Diagn. déc, vol.36, issue.12, 2016. ,
, Fetal Diagn Ther, vol.35, issue.3, pp.204-215, 2014.
Noninvasive prenatal testing of trisomies 21 and 18 by massively parallel sequencing of maternal plasma DNA in twin pregnancies: Sequencing-based prenatal noninvasive fetal trisomy test in twin pregnancies, Prenat Diagn. avr, vol.34, issue.4, pp.335-375, 2014. ,
,
, Fetal Aneuploidy Detection by Cell-Free DNA Sequencing for Multiple Pregnancies and Quality Issues with Vanishing Twins, J Clin Med. 25 juin, vol.3, issue.3, pp.679-92, 2014.
Performance of screening for aneuploidies by cell-free DNA analysis of maternal blood in twin pregnancies, Ultrasound Obstet Gynecol. janv, vol.45, issue.1, pp.61-67, 2015. ,
Noninvasive prenatal testing (NIPT) in twin pregnancies with treatment of assisted reproductive techniques (ART) in a single center, Prenat Diagn. juill, vol.36, issue.7, pp.672-681, 2016. ,
Prospective screening for trisomies by cell-free DNA testing of maternal blood in first trimester twin pregnancies, Ultrasound Obstet Gynecol Off J Int Soc Ultrasound Obstet Gynecol. 11 mars, 2016. ,
,
, Aneuploidy Screening Using Noninvasive Prenatal Testing in Twin Pregnancies
, Ultrasound Obstet Gynecol Off J Int Soc Ultrasound Obstet Gynecol. 19 mai, 2016.
,
, Noninvasive twin zygosity assessment and aneuploidy detection by maternal plasma DNA sequencing: Noninvasive twin zygosity and aneuploidy detection
, Prenat Diagn. juill, vol.33, issue.7, pp.675-81, 2013.
Cell-free fetal DNA analysis in maternal plasma as a screening test for trisomy 21, 18 and 13 in twin pregnancies, Ultrasound Obstet Gynecol Off J Int Soc Ultrasound Obstet Gynecol, 2017. ,
High-throughput massively parallel sequencing for fetal aneuploidy detection from maternal plasma, PloS One, vol.8, issue.3, p.57381, 2013. ,
Determination of fetal DNA fraction from the plasma of pregnant women using sequence read counts, Prenat Diagn. août, vol.35, issue.8, pp.810-815, 2015. ,
DNA sequencing of maternal plasma to identify Down syndrome and other trisomies in multiple gestations, Prenat Diagn. août, vol.32, issue.8, pp.730-734, 2012. ,
,
, Noninvasive Prenatal Determination of Twin Zygosity by Maternal Plasma DNA Analysis, Clin Chem. 2 janv, vol.59, issue.2, pp.427-462, 2013.
Sensitivity of Noninvasive Prenatal Detection of Fetal Aneuploidy from Maternal Plasma Using Shotgun Sequencing Is Limited Only by Counting Statistics, Bridger JM, éditeur. PLoS ONE. 3 mai, vol.5, issue.5, p.10439, 2010. ,
,
, Pregnancies conceived using assisted reproductive technologies (ART) have low levels of pregnancy-associated plasma protein-A (PAPP-A) leading to a high rate of false-positive results in first trimester screening for Down syndrome, Hum Reprod Oxf Engl. juin, vol.24, issue.6, pp.1330-1338, 2009.
Cellfree fetal DNA testing in singleton IVF conceptions, Hum Reprod Oxf Engl. 1 avr, vol.33, issue.4, pp.572-580, 2018. ,
, Annexe II : Formulaire de recueil des issues de grossesses envoyé aux prescripteurs
Information sur les conditions de recueil et d'envoi des échantillons par le laboratoire CERBA ,